Clinical evaluation including 12-lead ECG and transthoracic echocardiography was performed in all cases. Cardiovascular magnetic resonance and 24-hour Holter monitoring were performed. The EP characteristics of ARVC were assessed by EP study, and the results were correlated with genetic testing of 9 genes that have previously been reported to be related to ARVC, including plakophilin-2 (PKP2), desmocollin-2 (DSC2), desmoglein-2 (DSG2), desmoplakin (DSP), plakoglobin (JUP), transforming growth factor-β3 (TGFβ3), transmembrane protein 43 (TMEM43), desmin (DES), and Lamin A/C (LMNA).
A rrhythmogenic right ventricular cardiomyopathy (ARVC) is a heritable cardiac disease characterized by fibrofatty replacement of the right ventricle and ventricular arrhythmias (VAs). [1] [2] [3] Approximately 30% to 50% of patients have genetic abnormalities with an autosomal dominant inheritance pattern 4 but with incomplete penetrance and a highly variable clinical expression. Genetic studies have identified mutations in several genes associated with ARVC, including 5 desmosomal and 4 nondesmosomal genes. [5] [6] [7] [8] [9] [10] [11] [12] Previous studies have shown that genetic identification is related to different clinical characteristics of ARVC. [13] [14] [15] [16] However, the correlation between genotype and VA features remains unclear.
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Methods
Study Population
A total of 90 unrelated Chinese subjects with definite (n=69), borderline (n=15), or possible (n=6) diagnosis of ARVC and 300 age-, sex-, and ethnicity-matched healthy control subjects were recruited for gene analysis at our center. ARVC was diagnosed in all patients according to the revised diagnostic Task Force Criteria. 17 None of the control subjects had a history of cardiovascular or other systemic diseases.
This study was performed in accordance with the principles of the Declaration of Helsinki and approved by the Ethics Committees of our hospital. The informed consent for the electrophysiological (EP) study and genetic testing was provided by all participants. EP study was not performed on the control subjects.
EP Study
All 90 subjects were studied in the postabsorptive state under conscious sedation, and the procedures were performed before genetic testing. All antiarrhythmic drugs were discontinued for ≥5 half-lives before the procedure, except for amiodarone, which was discontinued for ≥1 month. Venous access was obtained from the femoral veins. Conventional EP study was performed after positioning of multipolar catheters in the right ventricle and in the area of His bundle (LabSystem Pro, Bard Electrophysiology, Lowell, MA).
Arrhythmias were induced according to standard protocols by using burst ventricular pacing (≤200 ms) and programmed stimulation up to 3 ventricular extra stimuli until ventricular refractoriness at 2 sites. Intravenous isoproterenol was also used (maximum dose, 6 µg/min) when necessary to induce ventricular tachycardia (VT). VT with a rate ≥300 bpm was considered as ventricular flutter. 18 Induced VTs were compared with 12-lead ECGs or implantable cardiac-defibrillatorstored electrograms of the clinical VT when available. The number and morphology of both spontaneous and induced VTs were recorded.
Mutation Analysis
Nine disease genes of ARVC, including PKP2, DSC2, DSG2, DSP, JUP, TGFβ3, TMEM43, DES, and LMNA, were genotyped with multiplexing targeted resequencing in all the subjects diagnosed with ARVC and healthy controls. Genomic DNA was extracted from whole blood and was used to construct DNA libraries. The coding exons and their flanking intronic regions (5 bp) were captured by using SureSelect Target Enrichment system (Agilent Technologies, Santa Clara, CA) and subsequently sequenced on GAIIx (Illumina, San Diego, CA). Detailed DNA sequencing and genotyping methods are described in the online-only Data Supplement.
The common polymorphisms were excluded by presence in the healthy controls. The remaining variants were confirmed by Sanger capillary sequencing in 2 directions. Variants were considered to be pathological if they were absent in 300 healthy controls and with one of the following criteria: (1) previously reported to be pathological, (2) nonsense and indels (either frameshift or in-frame) mutations, (3) novel missense mutations indicated a damaging effect by anyone of PolyPhen-2 19 (http://genetics.bwh.harvard.edu/pph2/) and SIFT 20 (http://sift.jcvi.org/), and (4) novel variations destroyed existing splice site predicted by Human Splicing Finder 21 (http://www.umd.be/HSF/).
Statistical Analysis
Categorical variables are expressed as frequencies (n) and percentages (%). Continuous data are expressed as mean±SD or median (25-75 percentiles) for normally distributed and skewed variables, respectively. Normal distribution was assessed using Kolmogorov-Smirnov test. Categorical variables were compared using the Pearson χ 2 test or Fisher exact test where appropriate. Continuous variables were compared across groups using the Student t test or Mann-Whitney U test. Statistical significance was set at P<0.05. All statistical analyses were performed in SPSS 18.0 (SPSS, Chicago, IL).
Results
Study Patients
Ninety subjects diagnosed with ARVC, including 70 (78%) men, were enrolled in the study ( Table 1 ). The mean age at inclusion was 37±12 years. The age at first presentation of symptoms was 33±12 years (range, 11-68 years). The time of the onset of any symptoms to the time of diagnosis was 26 months (9-67 months). All subjects had recorded VAs. There were 69 (77%) subjects with a history of sustained or nonsustained VT, and the others had only frequent premature ventricular complex. The diagnosis was incidental in 7 (8%) subjects with asymptomatic premature ventricular complexes. Twenty-six (29%) subjects had a history of syncope.
Mutation Analysis
A total of 73 nonsynonymous and 5 splicing variants were identified in the study. Twenty-five were excluded as common polymorphisms or neutral rare variants ( Table II in the online-only Data Supplement) according to the criteria listed above. Eventually, 53 mutations were identified in 57 (63%) subjects. Thirty-seven were novel ( Table III in the online-only Data Supplement). Fifty (94%) of the mutations were located in desmosomal genes, especially in PKP2 (31 mutations, 58%). Only 3 mutations were found in nondesmosomal genes (2 in TMEM43 and 1 in TGFβ3). No mutation was identified in DES or LMNA.
Single mutation was identified in 38 (42%) subjects: 28 in PKP2, 5 in DSG2, 2 in DSC2, and 1 each in DSP, JUP, and TMEM43 genes. Nineteen (21%) subjects carried multiple mutations: 4 with homozygous mutations (3 in DSG2 and 1 in PKP2 with an additional JUP heterozygous mutation), 4 with compound mutations, and 11 with digenic heterozygous mutations. Forty (44%) subjects carried PKP2 mutation.
EP Findings
A total of 135 VTs (range, 1-9) were induced in 56 (62%) subjects, with a mean cycle length of 300±60 ms. There were 83 induced VTs with a rate ≥200 bpm in 45 subjects and 6 ventricular flutters in 6 subjects. The induced VTs with left bundle-branch block (LBBB) and superior axis were observed in 50 subjects and LBBB with inferior axis in 18 subjects. Right bundle-branch block-type VTs were induced in 5 subjects. Fourteen subjects had >1 type of VT, among whom 1 subject had all 3 types. Fourteen clinical VTs in 13 subjects could not be induced during EP study. Sustained VT was not induced in subjects without a VT history.
Genotype-Phenotype Correlation
With Epidemiological Findings
Clinical characteristics of subjects with and without mutations were compared ( Table 1 ). The sex ratio was comparable between mutation carriers and noncarriers. The age at onset of cardiovascular symptoms (including palpitation, shortness of breath, dizziness, and syncope) was similar (34±12 versus 32±14 years), as well as the median time from the onset to diagnosis (36 versus 23 months).
A clinical history of VT was more common in the mutation carriers (89% versus 55%; P<0.001). A comparison of Task Force Criteria in mutation carriers and noncarriers showed that negative T waves in V 1 to V 3 occurred more often in the mutation carriers (61% versus 33%; P=0.016), as well as structural minor Task Force Criteria (30% versus 0%; P<0.001). No significant differences were demonstrated in other criteria.
Syncope occurred more often in subjects with multiple mutations (58%) as compared with those with single mutation (58% versus 24%; P=0.018). Syncope history was also present at a higher incidence in subjects with digenic mutation in comparison with all the others (67% versus 23%; P=0.004).
PKP2 mutation carriers had more VT history (95% versus 62%; P<0.001), more frequent LBBB-type VT with superior axis (80% versus 56%; P=0.024), and negative T waves in leads V 1 to V 3 (65% versus 40%; P=0.021). December 2013
With EP Findings
VT was significantly more often induced in mutation carriers than noncarriers (75% versus 39%; P=0.001). In addition, in 56 patients with inducible VT, a rate ≥200 bpm was also more predominant in the mutation carriers (88% versus 54%; P=0.013; Table 2 ). LBBB-type VT with inferior axis was also more often induced in these patients compared with noncarriers (40% versus 8%; P=0.042). The proportion of inducible LBBB-type VT with superior axis, right bundle-branch block-type VT, as well as the average number of VT induced during the EP study were similar between both groups. None of these parameters could be explained by multiple mutations. However, PKP2 mutation carriers had a significantly higher ratio of induced fast VT with a rate ≥200 bpm (91% versus 67%; P=0.041).
Discussion
The results of this study showed correlation between genotype and VA features in subjects diagnosed with ARVC. Pathogenic mutations were detected in >60% subjects, predominantly in desmosomal genes. Subjects with mutations not only had a higher proportion of VT history, but also a higher ratio of relatively fast VT (≥200 bpm) induced during EP study. PKP2 mutation carriers also demonstrated these associations. Multimutations were found in nearly 25% patients but without obvious correlation in all these VA features.
Several genes, mostly those encoding desmosomal proteins, have been identified as causative in ARVC, especially PKP2. 4, 6, 13, 14 PKP2 was also the most common gene in our study, accounting for more than half (58%) of the identified mutations in 44% subjects diagnosed with ARVC. VT history and fast VT inducement during EP study were more often seen in the carriers. Previous studies of Chinese subjects diagnosed with ARVC found PKP2 mutation in 18% to 39% of probands 22, 23 without significant difference in clinical characteristics. Small sample size of those studies might explain the differences compared with our results.
Only 3 nondesmosomal mutations were identified in 2 of the study subjects, and no mutations were detected in DES or LMNA genes. These findings suggested that desmosomal genes, especially PKP2, are the main disease-causing genes, whereas TMEM43, TGFβ3, DES, and LMNA are relatively rare in Chinese subjects diagnosed with ARVC.
Recently, compound and digenic heterozygous mutation had been found to play an important role in the expression of the disease, 5, 24, 25 with association with disease severity. In our study, the history of clinical VT and syncope was more common in multimutation carriers and progressively decreasing in single-mutation carriers and noncarriers. Such findings show a gene dose effect on the ARVC phenotypes. In addition, the high prevalence of multimutations in our cohort indicates the need for comprehensive screening of all known diseasecausing genes.
Several studies have found an association of ARVC genetic mutations with findings at EP study. La Gerche et al 26 screened 5 desmosomal genes in 47 athletes with complex VA of right ventricular morphology and right ventricular structural abnormalities and found that the induction of sustained VT or ventricular fibrillation on EP study tended to favor desmosomal mutation carriers. A study of 23 patients with ARVC showed that the inducibility of ventricular fibrillation in EP study was similar in those with and without desmosomal mutations. 4 In another cohort of 91 subjects diagnosed with ARVC, 27 desmosomal mutation was found to be associated with positive ventricular stimulation in EP testing. These studies indicated that genotype of patients with ARVC might be related to the EP manifestations. Our study analyzed the correlation between genotype and phenotype and for the first time showed that the varied expression in EP study, especially VA features, was associated with the genotype of patients.
Consisting with our findings, a recent study reported that desmoplakin mutations caused significant alterations in conduction-depolarization kinetics in both mouse and man, 16 and a significantly greater proportion of DSP flx\+ mice developed inducible VT. Although the number of VTs induced was similar between mutation carriers and noncarriers in our study, the inducible fast VT with a rate ≥200 bpm was more frequently seen in patients with mutations.
Study Limitations
It is still a challenge to determine the pathogenicity of all novel mutations for the genotype-phenotype association studies. Although 300 healthy controls (600 chromosomes) were used in this study to exclude neutral polymorphisms, with the mutation pathogenic potential assigned by bioinformatics prediction, the absence of the analysis of disease cosegregation in pedigree and the evaluation of gene/mutation function in animal model might still lead to overestimated prevalence of pathogenic mutations. In addition, the arrhythmia events during long-term follow-up should be more important to elucidate the effect of pathogenic mutations. We plan to further explore the association of genotypes with clinical outcomes of ARVC in the next phase of the study.
Conclusions
In this comprehensive genetic study of subjects diagnosed with ARVC, pathogenic gene mutations were found in nearly two thirds of subjects, with multimutations in more than one fifth of these subjects. The PKP2 mutation was the most common causative mutation of ARVC. Mutation carriers had not only a higher proportion of VT history but also a higher ratio of inducible fast VT with a rate ≥200 bpm during EP study. PKP2 mutation carriers also demonstrated the same association. Other differences between mutation carriers and those without mutations were also observed.
